{"title":"ct引导下经皮放射性125I近距离治疗局部晚期胰腺癌。","authors":"Peng Du, Liangliang Meng, Zenan Chen, Xiao Zhang","doi":"10.1177/10849785251380365","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To explore the efficacy and safety of <sup>125</sup>I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). <b><i>Methods:</i></b> A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive <sup>125</sup>I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive <sup>125</sup>I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. <b><i>Results:</i></b> All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. <b><i>Conclusions:</i></b> Coaxial puncture <sup>125</sup>I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CT-Guided Percutaneous Radioactive <sup>125</sup>I Brachytherapy for Locally Advanced Pancreatic Cancer.\",\"authors\":\"Peng Du, Liangliang Meng, Zenan Chen, Xiao Zhang\",\"doi\":\"10.1177/10849785251380365\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Purpose:</i></b> To explore the efficacy and safety of <sup>125</sup>I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). <b><i>Methods:</i></b> A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive <sup>125</sup>I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive <sup>125</sup>I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. <b><i>Results:</i></b> All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. <b><i>Conclusions:</i></b> Coaxial puncture <sup>125</sup>I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.</p>\",\"PeriodicalId\":55277,\"journal\":{\"name\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10849785251380365\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10849785251380365","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
CT-Guided Percutaneous Radioactive 125I Brachytherapy for Locally Advanced Pancreatic Cancer.
Purpose: To explore the efficacy and safety of 125I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). Methods: A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive 125I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive 125I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. Results: All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. Conclusions: Coaxial puncture 125I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.
期刊介绍:
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.